4D Molecular Therapeutics Inc

In accordance with the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 and Rule 14a-21 under the Exchange Act, the Company requests that our stockholders cast a non-binding advisory vote to approve the compensation of our named executive officers as disclosed in this Proxy Statement pursuant to the SEC’s compensation disclosure rules. This proposal, commonly known as a “say-on-pay” proposal and vote, is not intended to address any specific item of compensation, but rather the overall compensation of our named executive officers and the philosophy, policies, and practices described in this Proxy Statement.

We encourage our stockholders to review the “Executive Compensation” section of this Proxy Statement for additional detail regarding the compensation of our named executive officers.

As an advisory approval, this proposal is not binding upon us, our Board or our Compensation Committee, which are responsible for the design and administration of our executive compensation program. However, we, our Board and our Compensation Committee value the opinions of our stockholders expressed through your vote on this proposal and will carefully consider stockholder feedback and the results of say-on-pay votes when making future compensation decisions. Accordingly, we ask our stockholders to vote on the following resolution at the Annual Meeting:

“RESOLVED, that the stockholders of 4D Molecular Therapeutics, Inc. approve, on an advisory, non-binding basis, the compensation of 4D Molecular Therapeutics, Inc.’s named executive officers as disclosed in 4D Molecular Therapeutics, Inc.’s Proxy Statement for the 2025 Annual Meeting of Stockholders pursuant to the compensation disclosure rules of the SEC, including the section titled “Executive Compensation,” the 2024 Summary Compensation Table and other related tables and disclosures.”

FORTHE FOREGOING RESOLUTION TO APPROVE, ON AN ADVISORY, NON-BINDING BASIS,

THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.